Fewer than a tenth of individuals who could benefit from obesity jabs such as Wegovy can access them, warns the World Health Organization as it issues its initial recommendations on the therapies.
Considering over a billion individuals worldwide currently living with obesity, it is advocating for broader and more equitable availability to this class of drugs.
Per estimates, more than two billion could be obese by 2030 unless action is taken.
"The latest guidelines affirms that obesity is a chronic disease that can be treated with holistic and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and logistical bottlenecks are significant obstacles to broad availability to the injections that can help people shift substantial weight, notes the body.
Skinny Jab Shortage
Despite the current most optimistic outlook, the supply of these medications might only reach about 100 million people – less than 10% of eligible patients, according to the health organization.
The advice encourages nations and manufacturers to increase availability, by approaches such as voluntary licensing.
A patent on the active ingredient – the main component of the drug Wegovy – is due to expire in a number of countries in 2026.
How Obesity Drugs Operate
These medications replicate a biological compound to reduce digestion speed, suppress the appetite and increase feelings of fullness so users consume fewer calories.
People usually begin shedding pounds after several weeks of beginning the weekly injections.
Research points to people may regain a significant portion within a year of stopping the treatment, when their normal hunger resume.
To be above a healthy weight elevates your chance for contracting health problems, such as type 2 diabetes, heart disease, brain attack, and specific cancers.
Obesity impacts people in all nations and was responsible for 3.7 million fatalities worldwide in 2024, as per the health agency.